# Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

> **NCT07290621** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 30 (estimated)

## Conditions studied

- Oropharyngeal Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07290621
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2030-02
- **Final completion:** 2033-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290621, "Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07290621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*